{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=abraxane&page=15", "query": { "intervention": "abraxane", "page": 15 }, "page_size": 10 }, "pagination": { "page": 15, "page_size": 10, "total_count": 2451, "total_pages": 246, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=abraxane&page=16&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=abraxane&page=14&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-27T05:29:38.030Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00408070", "title": "Bevacizumab Study With Carboplatin & Paclitaxel in Ovarian, Fallopian Tube or Primary Peritoneal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Cancer", "Peritoneal Cancer", "Fallopian Tube Cancer", "Stage 3 Cancer", "Stage 4 Cancer" ], "interventions": [ { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UConn Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "FEMALE", "summary": "19 Years and older · Female only" }, "enrollment_count": 5, "start_date": "2006-10", "completion_date": "2009-10", "has_results": true, "last_update_posted_date": "2018-03-08", "last_synced_at": "2026-10-27T05:29:38.030Z", "location_count": 1, "location_summary": "Farmington, Connecticut", "locations": [ { "city": "Farmington", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT00408070" }, { "nct_id": "NCT07492680", "title": "A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "BMS-986504", "type": "DRUG" }, { "name": "Daraxonrasib", "type": "DRUG" }, { "name": "Nivolumab + Relatlimab FDC", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Pumitamig", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 260, "start_date": "2026-07-27", "completion_date": "2032-05-20", "has_results": false, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-10-27T05:29:38.030Z", "location_count": 16, "location_summary": "San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 10 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07492680" }, { "nct_id": "NCT01485848", "title": "EP-100 Plus Paclitaxel Versus Paclitaxel Alone in Patients With Ovarian Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Cancer Recurrent" ], "interventions": [ { "name": "EP-100", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Esperance Pharmaceuticals Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 49, "start_date": "2012-02", "completion_date": "2014-05", "has_results": false, "last_update_posted_date": "2014-06-10", "last_synced_at": "2026-10-27T05:29:38.030Z", "location_count": 15, "location_summary": "Greenbrae, California • San Francisco, California • Louisville, Kentucky + 11 more", "locations": [ { "city": "Greenbrae", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Covington", "state": "Louisiana" }, { "city": "Shreveport", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT01485848" }, { "nct_id": "NCT00005078", "title": "Tirapazamine, Carboplatin, and Paclitaxel in Treating Patients With Advanced Malignant Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "carboplatin", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "tirapazamine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 44, "start_date": "2000-03", "completion_date": "2012-07", "has_results": false, "last_update_posted_date": "2015-06-08", "last_synced_at": "2026-10-27T05:29:38.030Z", "location_count": 4, "location_summary": "Duarte, California • Los Angeles, California • Pasadena, California + 1 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Pasadena", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005078" }, { "nct_id": "NCT00787852", "title": "A Study of Dasatinib With Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer (NSCLC)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Group 1: Radiation, Paclitaxel,Carbo, Dasatinib days 1-47", "type": "DRUG" }, { "name": "Group 2: Radiation, Paclitaxel, Carbo, Dasatinib days 1-38", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Brown University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 11, "start_date": "2009-03", "completion_date": "2011-12", "has_results": true, "last_update_posted_date": "2014-07-30", "last_synced_at": "2026-10-27T05:29:38.030Z", "location_count": 1, "location_summary": "Providence, Rhode Island", "locations": [ { "city": "Providence", "state": "Rhode Island" } ], "official_url": "https://clinicaltrials.gov/study/NCT00787852" }, { "nct_id": "NCT07743190", "title": "A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early-Stage Triple Negative Breast Cancer (TNBC) Patients With High Tumor-Infiltrating Lymphocytes (TILs)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Triple Negative Breast Cancer (TNBC)", "Elevated Tumor-Infiltrating Lymphocytes" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxcel", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Medical University of South Carolina", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 55, "start_date": "2027-01-01", "completion_date": "2034-05-29", "has_results": false, "last_update_posted_date": "2026-10-15", "last_synced_at": "2026-10-27T05:29:38.030Z", "location_count": 2, "location_summary": "Syracuse, New York • Charleston, South Carolina", "locations": [ { "city": "Syracuse", "state": "New York" }, { "city": "Charleston", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT07743190" }, { "nct_id": "NCT00032032", "title": "Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "carboplatin", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 69, "start_date": "2002-05", "completion_date": "2010-01", "has_results": false, "last_update_posted_date": "2016-12-01", "last_synced_at": "2026-10-27T05:29:38.030Z", "location_count": 51, "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Ames, Iowa + 23 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Ames", "state": "Iowa" }, { "city": "Des Moines", "state": "Iowa" }, { "city": "Des Moines", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT00032032" }, { "nct_id": "NCT00084448", "title": "Paclitaxel and Celecoxib in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Cancer", "Primary Peritoneal Cavity Cancer" ], "interventions": [ { "name": "celecoxib", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gynecologic Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": null, "start_date": "2004-04", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-07-09", "last_synced_at": "2026-10-27T05:29:38.030Z", "location_count": 1, "location_summary": "Iowa City, Iowa", "locations": [ { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT00084448" }, { "nct_id": "NCT00006276", "title": "Micellar Paclitaxel to Treat Severe Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Psoriasis" ], "interventions": [ { "name": "Micellar Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 25, "start_date": "2000-09", "completion_date": "2002-10", "has_results": false, "last_update_posted_date": "2008-03-04", "last_synced_at": "2026-10-27T05:29:38.030Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006276" }, { "nct_id": "NCT01792050", "title": "Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "Docetaxel", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Indoximod", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "NewLink Genetics Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 169, "start_date": "2013-02", "completion_date": "2017-07-07", "has_results": false, "last_update_posted_date": "2020-05-28", "last_synced_at": "2026-10-27T05:29:38.030Z", "location_count": 28, "location_summary": "Gainesville, Florida • Tampa, Florida • Titusville, Florida + 24 more", "locations": [ { "city": "Gainesville", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Titusville", "state": "Florida" }, { "city": "Weston", "state": "Florida" }, { "city": "Athens", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01792050" } ] }